Skip directly to content

Our History

Pfizer has a long history of innovation in healthcare and research, across the world and in Australia. 

In 1956 Pfizer commenced operations in Australia with just six people: an accountant, a medical director, two employees responsible for handling sample storage and two secretaries. Many of the diseases that significantly impacted the lives of Australians in the 60s and 70s can now be managed through medication because of the hard work and commitment of these first Pfizer employees, and the many colleagues who have since followed in their footsteps.
 
Today, Pfizer Australia employs 1,700 colleagues in a variety of fields including science, medical, regulatory affairs, manufacturing, sales and marketing, health economics, research and development. Every day our people work together with the sole purpose of ensuring that Australians can access new and innovative medicines that are being used to treat some of the most feared conditions of our time.

Pfizer in Australia

1956  

Incorporation of Pfizer Australia

1959

Opening of West Ryde head office and manufacturing facility

1977

Launch of sustained-release drug ‘Eryc’ (enteric-coated pellets of erythromycin)

1979

Acquisition of G-Chem

1980s

Discover and launch of the world’s first patient-controlled analgesia (PCA) device

1984

Acquisition of David Bull Laboratories

1988

Establishment of joint venture with CSIRO to develop new drugs under Keating government’s “Factor f” scheme

1993/4

Triple rollout of major new medicines: Zoloft®, Norvasc® and Zithromax®

1997

Launch of Lipitor®

2003

Acquisition of Pharmacia (including the manufacturing facility in Perth)

2004

Acquisition of CSL Animal Health

2006

Sale of Pfizer Consumer Health

2009

Acquisition of Wyeth

2012

Sale of Pfizer Nutrition

2013

Spin off of Pfizer’s Animal Health unit, Zoetis

2014

Acquisition of Baxter’s vaccines portfolio

2015

Acquisition of Hospira

2016

Pfizer celebrates 60 years in Australia

Our Future

2016 is a wonderful opportunity to acknowledge and celebrate the contribution we have made to improving the health of Australians. We have an extensive medicines portfolio, a promising pipeline and an ongoing commitment to innovation that includes significant investment in local research and development.